Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01430091 · ClinicalTrials.gov registry record · Phase 1
A Relative Bioavailability Study of a Prasugrel Orally Disintegrating Tablet
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT01430091 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 18 participants.
The verdict
NCT01430091, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This study compares the clinical tablet formulation of prasugrel taken orally with an orally disintegrating tablet (ODT) taken orally. The study will evaluate the amount of prasugrel active metabolite circulating in the blood for each treatment.
Interventions
- DRUG Prasugrel (clinical formulation)
- DRUG Prasugrel (Orally Disintegrating Tablet [ODT])
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2011-09 |
| Est. Completion | 2011-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01430091
The ClinicalTrials.gov registry entry for NCT01430091 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Prasugrel (clinical formulation) is the first listed.
NCT01430091 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01430091 about?
NCT01430091 is a clinical study titled "A Relative Bioavailability Study of a Prasugrel Orally Disintegrating Tablet". This study compares the clinical tablet formulation of prasugrel taken orally with an orally disintegrating tablet (ODT) taken orally. The study will evaluate the amount of prasugrel active metabolite circulating in the blood for each treatment.
What is the current status of trial NCT01430091?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2011-09. Estimated completion is 2011-10.
What interventions are being tested in trial NCT01430091?
The interventions under investigation include: Prasugrel (clinical formulation) (DRUG), Prasugrel (Orally Disintegrating Tablet [ODT]) (DRUG).
Who is sponsoring clinical trial NCT01430091?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.